In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Inspector General Warns CMS It Is Overpaying For Wound Pumps

This article was originally published in The Gray Sheet

Executive Summary

HHS' Office of the Inspector General is advising CMS to take more caution in paying for negative pressure wound therapy pumps by requiring suppliers to submit patient medical records with all Medicare claims

You may also be interested in...



HHS IG Urges Medicare To Crack Down On Negative Pressure Pump Payments

CMS will consider whether it has sufficient data to curb payments for negative pressure wound therapy pumps, the agency said in response to a March 19 report by the HHS Office of Inspector General

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.

UsernamePublicRestriction

Register

MT025025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel